|
AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). |
|
|
Employment - Janssen Research & Development |
Patents, Royalties, Other Intellectual Property - Janssen Research & Development |
Travel, Accommodations, Expenses - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
Patents, Royalties, Other Intellectual Property - Patent for making cell blocks in cytology. |
Travel, Accommodations, Expenses - Janssen Oncology |
|
|
Employment - Janssen Research & Development |
Travel, Accommodations, Expenses - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
Travel, Accommodations, Expenses - Janssen Research & Development |
|
|
Employment - Johnson & Johnson |
Leadership - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
Research Funding - Johnson & Johnson |
Travel, Accommodations, Expenses - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
Patents, Royalties, Other Intellectual Property - Janssen Research & Development |
|
|
Employment - Janssen Oncology |
Stock and Other Ownership Interests - Johnson and Johnson |
|
|
Employment - Janssen Research & Development |
Leadership - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
Honoraria - Wellster Healthtech Group |
Consulting or Advisory Role - Wellster Healthtech Group |
Patents, Royalties, Other Intellectual Property - Founder of Vitruvo eHealth and Developer of a Digital Medicine Application |
|
|
|
|
|
|
Research Funding - PathomIQ |
Patents, Royalties, Other Intellectual Property - I received royalty distribution from Memorial Sloan Kettering Cancer Center as the inventor of 2 patents. |
|
|
|
Stock and Other Ownership Interests - PathomIQ |
Research Funding - PathomIQ |
(OPTIONAL) Uncompensated Relationships - PathomIQ |
|
|
Stock and Other Ownership Interests - Colby Pharmaceutical; PathomIQ |
Patents, Royalties, Other Intellectual Property - Issued patents: 9,023,837 8,466,130 7,491,849 7,453,011 7,235,695 7,186,825 7,026,347 6,982,351 6,794,545 5,880,161 5,541,230 |
Travel, Accommodations, Expenses - Dhristi |
|
|
Employment - PathomiQ; Senex Biotechnology |
Leadership - AIQ Solutions; PathomIQ; Senex Biotechnology |
Stock and Other Ownership Interests - AIQ Solutions; PathomIQ; Senex Biotechnology |
Consulting or Advisory Role - Cullgen; Leidos Biomedical Research |
|
|
|
Stock and Other Ownership Interests - PathomIQ |
Patents, Royalties, Other Intellectual Property - Patents pending in the area of biomarker discovery using AI on histopathology data for patient outcome prediction. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics |
Honoraria - Janssen; Johnson and Johnson |
Consulting or Advisory Role - Fortis; Janssen Oncology; Teon Therapeutics |
|
|
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi |
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi |
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Pfizer |
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst) |